WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that its programs were the subject of five poster presentations at the fourth International AIDS Society Conference on Pathogenesis, Treatment, and Prevention (IAS) held this week, July 22-25, in Sydney, Australia. The data presented ranged from pre-clinical virology of new antiviral compounds in discovery to clinical studies of the Company’s lead compound, bevirimat, in healthy volunteers and HIV-positive patients.